JP Morgan Chase
AVIR icon

JP Morgan Chase’s Atea Pharmaceuticals AVIR Stock Holding History

JP Morgan Chase’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,000
Closed -$70K – 6629
2021
Q3 		$70K Buy
+2,000
New +$55.5K ﹤0.01% 5726

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

JP Morgan Chase's AVIR Position: Q1 2026 in Review

JP Morgan Chase reduced its Atea Pharmaceuticals (AVIR) stake by 30% in Q1 2026, selling an estimated $1.87M and leaving 940,157 shares worth $4.78M. The position accounts for ﹤0.01% of the portfolio, ranked #3350.

JP Morgan Chase first reported a position in AVIR in Q4 2020 and has held it in 22 quarters since. The position peaked at $4.81M in Q4 2025. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • JP Morgan Chase held 940,157 shares of Atea Pharmaceuticals worth $4.78M as of Q1 2026.
  • JP Morgan Chase sold 408,137 Atea Pharmaceuticals shares in Q1 2026, an estimated $1.87M.
  • Atea Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3350 holding.
  • JP Morgan Chase first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • JP Morgan Chase's Atea Pharmaceuticals position peaked at $4.81M in Q4 2025.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.